Skip to main content

Table 5 Accuracy of the GEP test and sentinel lymph node status

From: Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

  GEP Class SLN status
% (95% CI) % (95% CI)
RFS
 Sensitivity 70% (62–78%) 66% (57–74%)
 Specificity 71% (67–76%) 65% (58–71%)
 PPV 48% (41–55%) 52% (44–60%)
 NPV 87% (82–90%) 76% (69–82%)
DMFS
 Sensitivity 75% (66–83%) 67% (57–76%)
 Specificity 69% (65–74%) 62% (55–68%)
 PPV 40% (33–47%) 42% (34–50%)
 NPV 91% (87–94%) 82% (76–88%)
MSS
 Sensitivity 85% (72–94%) 79% (63–90%)
 Specificity 64% (60–69%) 58% (52–64%)
 PPV 19% (14–25%) 21% (15–28%)
 NPV 98% (95–99%) 95% (91–98%)
  1. CI confidence interval, DMFS distant metastasis-free survival, GEP gene expression profile, MSS melanoma-specific survival, NPV negative predictive value, PPV positive predictive value, RFS recurrence-free survival, SLN sentinel lymph node